Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthopediatrics (KIDS) Accumulated Expenses (2016 - 2026)

Orthopediatrics has reported Accumulated Expenses over the past 11 years, most recently at $12.8 million for Q1 2026.

  • For Q1 2026, Accumulated Expenses rose 12.74% year-over-year to $12.8 million; the TTM value through Mar 2026 reached $12.8 million, up 12.74%, while the annual FY2025 figure was $13.7 million, 1.4% down from the prior year.
  • Accumulated Expenses for Q1 2026 was $12.8 million at Orthopediatrics, down from $13.7 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $13.9 million in Q4 2024 and troughed at $4.4 million in Q1 2022.
  • A 5-year average of $10.1 million and a median of $11.3 million in 2023 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: decreased 8.6% in 2022 and later surged 67.93% in 2023.
  • Year by year, Accumulated Expenses stood at $6.7 million in 2022, then soared by 67.93% to $11.3 million in 2023, then grew by 22.63% to $13.9 million in 2024, then fell by 1.4% to $13.7 million in 2025, then decreased by 6.76% to $12.8 million in 2026.
  • Business Quant data shows Accumulated Expenses for KIDS at $12.8 million in Q1 2026, $13.7 million in Q4 2025, and $13.8 million in Q3 2025.